Teva seeks to add more patents to US suit against Momenta/Sandoz on Copaxone
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries is seeking to expand an existing lawsuit against Momenta Pharmaceuticals and Sandoz (Novartis) as it relates to their effort to market a generic version of Teva's blockbuster multiple sclerosis drug Copaxone (glatiramer acetate) in the US. Teva now says that the firms are infringing 10 patents, whereas an original complaint filed in August 2008 claimed only seven.